In this regard, the NGS custom melanoma panel appeared to be well suited for ctDNA analysis and showed significant correlation with ddPCR (reaching 100% concordance for mutations down to 0.8% of frequency), with the additional benefit of allowing the parallel monitoring of driver and target genes together with the assessment of the BRAF CNV. This evidence concerns the gene BRAF and melanoma.